

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/511,537	First Named Inventor: Tiden
Filing Date: October 15, 2004	Attorney Docket No.: 100647-1P US
Examiner: Mark L. Berch	Group Art Unit : 1624
Customer No.: 22466	Confirmation No.: 4417
Title: Thioxanthine Derivatives as Myeloperoxidase Inhibitors	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir,

Applicants submit herewith a list of patents and publications pursuant to the duty to disclose in accordance with 37 C.F.R. § 1.56.

In accordance with 37 C.F.R. § 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. § 1.56.

In accordance with the U.S. Patent Office's partial waiver of the requirement under 37 C.F.R. 1.98(a)(2)(i), only copies of the cited foreign patent documents, non-patent publications, and English language abstract(s) of non-English language patent(s)/patent application publication(s), cited in the accompanying PTO SB08 Form(s) are submitted herewith.

In addition, Applicant(s) wish to call to the Examiner's attention to the following commonly-owned co-pending patent application(s) and Office Action(s) issued therein:

- 1) U.S. Application Serial No. 11/756967, Attorney Docket No. 102288-2 US, filed on June 1, 2007;
- 2) U.S. Application Serial No. 11/577833, Attorney Docket No. 101584-1P US, filed on April 24, 2007; and
- 3) U.S. Application Serial No. 11/720913, Attorney Docket No. 101621-1P US, filed on June 5, 2007.

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed before the mailing of a **first Office Action** after the filing of a request for continued examination under 37 C.F.R. 1.114

It is respectfully requested that each of the patents and publications listed on the attached Form SB08, and other information cited therein, be considered by the Examiner and made of record in this application.

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 26-0166, referencing Attorney Docket No. 100647-1P US.

Respectfully submitted,
/Jacqueline M. Cohen/

Name: Jacqueline M. Cohen
Dated: January 15, 2008
Reg. No.: 51,574
Phone No.: 302-885-4269
Global Intellectual Property, Patents,
AstraZeneca
1800 Concord Pike
Wilmington
DE-19850-5437